Carcinoma Renal Cell
📧 Sign up to get email alerts when something new happens for Carcinoma Renal Cell.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-07EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorises a biosimilar version of bevacizumab (Abevmy) for multiple cancer indications, expanding access to this biologic therapy.
-
EMA approval · 2026-06-24EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG
Authorised approval for Yervoy (ipilimumab) with multiple indications including melanoma and various carcinomas and mesothelioma; decision d…
-
EMA withdrawal · 2021-11-25EMA Withdrawn: Equidacent (bevacizumab) — Centus Biotherapeutics Europe Limited
Equidacent (bevacizumab) has been withdrawn from the market in the European Medicines Agency record.
-
CLINICAL_TRIALS trial_result · 2018-10-12Clinical Trial Update: Personalized Targeted Inhibitors Treatment in Renal Cell Cancer [Phase 2]
A Phase 2 clinical trial evaluating personalized targeted inhibitors for renal cell carcinoma was terminated; results were posted in 2018.